GLP-1 Drugs Cut Stage IV Progression in 4 Cancers, With 10.0% vs 22.3% in Lung Cases
Updated
Updated · The ASCO Post · Jun 28
GLP-1 Drugs Cut Stage IV Progression in 4 Cancers, With 10.0% vs 22.3% in Lung Cases
3 articles · Updated · The ASCO Post · Jun 28
Summary
A 12,112-patient propensity-matched analysis found GLP-1 receptor agonists were linked to less metastatic progression in six of seven obesity-related cancers after diagnosis, with statistically significant benefits in lung, breast, colorectal and liver tumors.
In non-small cell lung cancer, stage IV progression was 10.0% with GLP-1 drugs versus 22.3% with DPP-4 inhibitors; breast was 10.2% versus 20.1%, colorectal 13.4% versus 22.2%, and hepatocellular carcinoma 18.9% versus 28.4%.
Prostate, pancreatic and renal cancers also showed fewer metastases in the GLP-1 group, but those differences were not statistically significant; adverse events were similar, with no higher pancreatitis signal.
Tumor data from The Cancer Genome Atlas linked high GLP-1 receptor expression to a 33% lower risk of death across the seven cancers, including a 45% lower risk in breast cancer.
Researchers and ASCO experts said the findings are observational and cannot prove causation, but the consistency across tumor types supports randomized trials to test whether GLP-1 drugs directly slow cancer progression.
Beyond weight loss, does this new class of drugs directly attack and slow down tumor growth?
Is this blockbuster medication a secret cancer fighter, or is there a simpler explanation?
GLP-1RAs and Cancer Metastasis: Emerging Evidence and Clinical Implications from ASCO 2026
Overview
The 2026 ASCO Annual Meeting highlighted exciting new research showing that GLP-1 receptor agonists (GLP-1RAs), commonly used for diabetes and weight management, may help reduce cancer metastasis. Early findings from retrospective, real-world studies suggest a promising link between GLP-1RA use and less cancer spread, sparking considerable interest in the oncology community. However, these results are still considered hypothesis-generating and need rigorous validation through future trials. As a result, experts recommend close attention to GLP-1RA use throughout cancer care, recognizing its potential as a novel approach in cancer management.